An active-comparator-controlled, open-label, parallel group study to evaluate the effect of survodutide on energy expenditure and fatty acid oxidation in subjects with obesity

A study to test whether survodutide improves how the body uses energy and breaks down fat in people with obesity.

To be enrolled in this study, you must meet certain requirements. You may be eligible to participate if
you meet the following criteria:

Study Duration: up to 44 weeks

Study Commitment: 1 screening visit
Two 4-day inpatient stays on the clinical research unit
~28-36 weeks of study medication intervention (site and remote visits)

Age: 18-65 years old

Sex: Male & Female

Conditions/Eligibility:
BMI 30-45
Willing to self-inject study medication or receive injection of study medication
Does not have Type 1 or Type 2 Diabetes
Non-smoker

Study Procedures:
Informed Consent
Demographics collection
Health and medication history
Physical Exam
ECG
Blood and urine collections
Vital signs (height, weight, BMI, HR, BP)
DXA and MRI
Indirect Calorimetry
Medication and dietary compliance checks
Medication administration
Questionnaires
Diet and physical activity counseling

Compensation: Up to $11,220